FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy

ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with previously treated metastatic CRC with a BRAF V600E mutation INDIANAPOLIS , Sept. 28, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the U.S.